anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing mesenchymal stem cells is provided to induce infiltration of microglia at a site where beta-amyloid is accumulated and treat beta-amyloid-related diseases. CONSTITUTION: A composition for treating beta-amyloid-relating diseases contains mesenchymal stem cells as active ingredient. The mesenchymal stem cells are isolated from bone marrow. The composition contains diluents. The beta-amyloid-relating disease is Alzheimer. The composition is used in the form of tablet, powder, pill, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterilization injection solution, and sterilization powder.
Deep brain stimulation (DBS) is the gold-standard treatment for patients with medication resistant motor complications of Parkinson's disease (PD) and provides the only opportunity to record and stimulate in the human basal ganglia. Most recently, the concurrent use of research electrocorticography (ECoG) during DBS surgery, including pioneering work from Pittsburgh, has further enabled basic neuroscience investigation of human cortical-subcortical network dynamics. The discovery that aberrant synchronization of rhythmic neuronal activity recorded in PD patients is suppressed by DBS has advanced the concept that measures associated with pathological activity may be used as biomarkers to control the delivery of DBS therapy. Pilot studies of aDBS in PD have reported promising clinical results from triggering DBS stimulation when the signal recorded from the DBS electrode showed a high level of oscillatory power in the beta frequency range (13 - 35 Hz). That approach, however, has important limitations. Most importantly, beta power recorded from the DBS lead is suppressed by movement including PD tremor, its detection is highly dependent on lead location and the recording montage needed to record during stimulation is incompatible with directional current steering, a recent innovation employing segmented stimulation contacts. The inherent complexity of the increased parameter space through DBS innovations also overwhelms standard programming techniques. Finally, use of additional biomarker signals (e.g., recorded from cortex) is likely to improve the ability to adaptively control DBS for disorders marked by complex multidimensional symptomatologies such as PD. The current proposal will establish methods for overcoming these limitations by developing techniques for multi-feature classification from ECoG recordings, using advanced machine learning algorithms.
Risk Summary

The available human data from a clinical lactation study detected small amounts of voclosporin in human milk. Following a single dose to lactating subjects, a fully breastfed infant was estimated to receive a daily infant dose of 0.00675 mg/kg, and relative infant dose of 1.4% the maternal weight-adjusted dose. No change is expected for infant exposure at steady state with maternal twice daily dosing (see Data). Available data from the clinical study and published scientific literature are insufficient to determine the effects of LUPKYNIS on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LUPKYNIS and any potential adverse effects on the breastfed infant from LUPKYNIS or from the medical condition of the mother.

Data   
Following a single 23.7 mg dose of voclosporin in healthy lactating subjects, an average of 0.00472 mg voclosporin was excreted in breast milk. Data showed that the voclosporin milk to maternal blood exposure ratio was in the range of 0.42 to 0.95. Based on the infant milk intake of 200 mL/kg/day, the highest estimated voclosporin dose ingested by fully breastfed infant was 1.4% of maternal weight-adjusted dose, which equals estimated daily infant dose of 0.00675 mg/kg/day. At steady state following maternal twice daily dosing regimen, the percent of voclosporin dose present in breast milk is expected to be similar to that following maternal single dose.
A dental flosser is provided for delivering to a mouth a moisture activated composition including a flavor agent. The dental flosser comprises a base portion forming a handle and terminating at a distal head portion. A pair of spaced apart arms extend from the head portion, each of the spaced apart arms having a proximal first end adjoining the head portion and a distal second end. A length of dental floss extends between the distal second ends of the arms. A surface of at least one arm of the pair of arms defines a cavity between the first end and the second end forming a well for accommodating the composition. The width of the cavity in a plane parallel to the surface of the at least one arm is substantially the same or greater than the width of the bottom of the cavity.
A naltrexone treatment study by Anton et al., released by the National Institutes of Health in February 2008 and published in the Archives of General Psychiatry, has shown that alcoholics having a certain variant of the opioid receptor gene (G polymorphism of SNP Rs1799971 in the gene OPRM1), known as Asp40, demonstrated strong response to naltrexone and were far more likely to experience success at cutting back or discontinuing their alcohol intake altogether, while for those lacking the gene variant, naltrexone appeared to be no different from placebo. The G allele of OPRM1 is most common in individuals of Asian descent, with 60% to 70% of people of Chinese, Japanese, and Indian ancestry having at least one copy, as opposed to 30% of Europeans and few Africans.

Because of the characteristics of the patient group in the US, the first study was done on white patients and the next without regard for ethnicity. Anton et al. found that patients of African descent did not have much success with naltrexone in treatment for alcohol dependence because of lacking the relevant gene.

As white patients with the gene had a five times greater rate of success in reducing drinking when given naltrexone than did patients without the gene, when used in a protocol of Medical Management (MM), Anton et al. concluded,

"Because almost 25% of the treatment-seeking population carries the Asp40 allele, genetic testing of individuals before naltrexone treatment might be worth the cost and effort, especially if structured behavioral treatment were not being considered."[30] This would enable treatment to be targeted by genetics to patients for whom it would be most effective. They noted, "Naltrexone is relatively easy to administer and free of serious adverse effects and, as we observed in the Asp40 carriers we studied, it appears to be highly effective."

Studies have found naltrexone to be more efficacious among certain white subjects, because of the genetic basis, than among black subjects, who generally do not carry the relevant gene variant. A 2009 study of naltrexone as an alcohol dependence treatment among African Americans failed to find any statistically significant differences between naltrexone and a placebo. Studies have suggested that carriers of the G allele may experience higher levels of craving and stronger "high" upon alcohol consumption, compared to carriers of the dominant allele, and naltrexone somewhat blunts these responses, leading to a reduction in alcohol use in some studies.
PROBLEM TO BE SOLVED: To obtain a composition for oxidation dyeing which can give coloration exerting good resistance against aggressive factors, e.g. shampoo, light, bad weather, permanent wave treatment, perspiration, friction and the like, by including a pyrazolopyrimidine and a cationic direct dye in a medium. SOLUTION: The objective composition for keratin fiber, e.g. human keratin fiber or the like such as hair, is obtained by including (A) at least one kind of pyrazolo[1,5-a]pyrimidines as an oxidation base and (B) at least one kind of cationic direct dyes in a medium suitable for dyeing. This composition contains no enzyme system capable of causing the oxidation of the pyrazolo[1,5- a]pyrimidines. The component A is preferably selected from a compound of the formula [R33-R36 are each H, a 1-4 C alkyl or the like; R is H, an aryl or the like; (i) is 0-3; (p), (q) and (n) are each 0 or 1] and an adduct salt with its acid or base. It is favorable that the component B is a cationic aminoanthraquinone or the like.
Essentially organic, non-metallic ribbon useful as a twist tie comprising polymeric material exhibiting glass/rubber transitional behavior. Polymeric ribbons deformed under tensile stress at 25 exhibit yield stress between about 500 and 9,000 psi. Discrete lengths of ribbon are capable of being disengagedly formed into fastly held twist ties by rotationally deforming terminal ends of said lengths about each other. Ribbons can comprise polymers, such as polyalkylene terephthalates, polyvinylchlorides, styrene-acrylonitrile copolymers and polystyrenes. Optional polymeric materials include elastomeric impact modifiers and plasticizers. Process for the production of such ribbon. Methods for using such ribbon.
A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in blood vessels of a patient is provided. The chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive product is administered at sites of the plaques formed in the patient's blood vessels. The chemical composition comprises, for example, one or more of d-limonene, propylene glycol, octanic acid, 2-octane, and glycerine. The chemical composition enables modification of the plaques by altering composition of the plaques. The modification comprises partial dissolution, complete dissolution or elimination of the plaques. The modification makes the plaques amenable to different forms of plaque treatment, for example, balloon angioplasty, stenting, atherectomy, etc. The modified plaques are eliminated from the body of the patient. The modification or elimination of the plaques facilitates treatment of cardiovascular diseases caused due to plaques formed in the blood vessels of the patient.
Chronic liver diseases are caused by hepatic viral infection, chemicals, and metabolic stress. The protein Grb2-associated binder 1 (Gab1) binds to various growth factor receptors, and triggers cell differentiation/survival signaling pathways. To identify signaling molecules involved in the progression of liver diseases, we performed reverse-phase protein microarray (RPMA)-based screening of hepatocytes isolated from humanized mice after acute HCV infection. Acute viral infection in humanized liver mice significantly decreased the level of hepatocyte p-Gab1. Moreover, hepatoma cells upon HCV infection decreased Gab1 mRNA at later times of infection (D3 to D5) and p-Gab1 level was inversely related to the production of TGF-β. In contrast, the level of p-Gab1 was increased in CCL4-induced fibrotic liver. Hepatoma cells showed elevation of p-Gab1, along with an increase in STAT3 and ERK activation, upon treatment with HGF (ligand of HGF receptor/c-Met) and CCL4. In Gab1 knockdown hepatoma cells, cell proliferative signaling activity was reduced but the level of activated caspase-3 was increased. These findings suggest that hepatocyte Gab1 expression may play a role in promoting liver fibrosis progression by triggering ERK activation and inhibiting apoptosis. It implies that the Gab1-mediated signaling pathway would be a promising therapeutic target to treat chronic liver diseases.
The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
This invention provides medicine compositions for treating urinary system, which is used to carry a carbon material containing 60 wt% or more of carbon in a water-containing carrier so as to make both form a medically acceptable water-containing carrier that carries carbon. The carbon material in each dose of medicine compositions of water-containing carrier that carries carbon is in the range from 0.1g/ml to 500 mg/ml, and the diameter of the carbon material is between 2nm and 2mm. The carbon material is further combined with metal particles selected from one of silver, platinum, gold, zinc or copper, or the group composed of these metals. The diameter of the metal particle is between 2 nm and 2 mm. The carbon material, or the carbon material combined with metal particles, contained in the medicine compositions can contact with the bladder or related organs inside animal, and have the functions of disinfection and lowering the cystitis, can control infection effectively and prevent the repetitive occurrence of cystitis, make the surface wound to be healed quicker and ease the disease of the cystitis sufferer. It can also be used regularly in concert with the medical personnel to keep the urinary system free of bacteria and prevent the occurrence of bacteriuria, cystitis and pyelonephritis.
Disclosed is a fully human antibody specifically inhibiting a connexin 26. The antibody is a recombinant immunoglobulin having the structure of scFv-Fc. scFv refers to a single-chain antibody comprising a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO: 1 and the amino acid sequence of the light chain variable region is set forth in SEQ ID NO: 2. Fc refers to a constant region. An amino acid sequence from the 41 st  to the 56 th  amino acids in an extracellular region of human connexin 26, i.e., KEVWGDEQADFVCNTL, is used as an antigen. The invention is obtained by employing a single-chain antibody phage display library and a screening technique. A biochemical analysis and an immunofluorescent identification of the antibody indicated that the antibody specifically recognizes the connexin 26 and inhibits an activity of a hemichannel formed by the connexin 26. An animal test showed that the antibody exerted a significant inhibitory effect on the activity of a hemichannel in a murine cochlear tissue slice. Therefore, the antibody can be used for the treatment of a disease associated with connexin mutation.
BACKGROUND: Plexins are large transmembrane receptors for the semaphorin family of signalling proteins. Semaphorin-plexin signalling controls cellular interactions that are critical during development as well as in adult life stages. Nine plexin genes have been identified in humans, but despite the apparent importance of plexins in development, only biallelic PLXND1 and PLXNA1 variants have so far been associated with Mendelian genetic disease.
METHODS: Eight individuals from six families presented with a recessively inherited variable clinical condition, with core features of amelogenesis imperfecta (AI) and sensorineural hearing loss (SNHL), with variable intellectual disability. Probands were investigated by exome or genome sequencing. Common variants and those unlikely to affect function were excluded. Variants consistent with autosomal recessive inheritance were prioritised. Variant segregation analysis was performed by Sanger sequencing. RNA expression analysis was conducted in C57Bl6 mice.
RESULTS: Rare biallelic pathogenic variants in plexin B2 (PLXNB2), a large transmembrane semaphorin receptor protein, were found to segregate with disease in all six families. The variants identified include missense, nonsense, splicing changes and a multiexon deletion. Plxnb2 expression was detected in differentiating ameloblasts.
CONCLUSION: We identify rare biallelic pathogenic variants in PLXNB2 as a cause of a new autosomal recessive, phenotypically diverse syndrome with AI and SNHL as core features. Intellectual disability, ocular disease, ear developmental abnormalities and lymphoedema were also present in multiple cases. The variable syndromic human phenotype overlaps with that seen in Plxnb2 knockout mice, and, together with the rarity of human PLXNB2 variants, may explain why pathogenic variants in PLXNB2 have not been reported previously.
PURPOSE:To obtain a plaster having excellent stretchability, giving uniform rate of application, allowing the pouring of water at need in use to improve the cooling effect, pasted to the body and useful as a remedying agent such as an anti-inflammatory or analgesic by using a cellulosic sponge as a substrate. CONSTITUTION:The objective plaster is an integrated laminate composed of a substrate 11 made of a cellulosic sponge and having a thickness of about 0.2-5mm, a tacky adhesive layer 13 applied to a surface of the substrate and a facing material 15 such as polypropylene film applied to the adhesive layer. A cellulosic sponge such as a sponge of a cellulose derivative (e.g. viscose or cellulose ether) can be used in addition to a sponge of cellulose. It has chemical stability, retains moderate amount of water in the substrate by pouring water to the plaster and keeps a sufficient cooling effect over a long period without deteriorating the feeling to the skin. The spreadability in the application of the tacky adhesive layer is improved, the amount of applied tacky adhesive agent is uniformized and the productivity is improved.
PURPOSE:To obtain a light-stabilized ubidecarenone-containing composition useful for chronic hypertension, etc., by mixing a coloring matter to ubidecarenone. CONSTITUTION:Ubidecarenone is mixed with a coloring matter. Used coloring matter is an oil-soluble coloring matter, a water-soluble coloring matter or the both, e.g. at least a species selected from a group comprising oil yellow OB (yellow color No.3), sudan II (red color No.5), tartrazine (yellow color No.4) and betacarotin. For instance, (oily) ubidecarenone raw powder hardly soluble in water is dissolved in dicapric propylene glycol, etc., to obtain a solution and solid components of coloring matter and anhydrous silicic acid, etc., are added to the solution. Then the solution is emulsified by a high-speed homogenizer to obtain a solution of coloring matter-containing ubidecarenone in an oily carrier. The resultant solution is directly used or used after obtaining ubidecarenone-containing powder as a final material by spray drying, etc.
The invention relates to an oil-control acne-removing composition, a skin care product and skin care gel thereof and a preparation method thereof. The oil-control acne-removing composition consists of 25-60 parts of tanshinone, 15-45 parts of guaiac sodium sulfonate and 10-30 parts of madecassoside in parts by weight. The oil-control acne-removing composition provided by the invention has the advantages that the three components are compounded according to a specific proportion, the synergistic effect of three active substances can be effectively exerted, and the activity of the composition can be more effectively exerted. The skin care product and skin care gel disclosed by the invention comprise 0.1-1.5% of the oil control acne removal composition by mass percent. The skin care product and skin care gel provided by the invention are added with the oil control acne removal composition, so that the oil control acne removal composition has a small addition amount and an excellent oil control acne removal effect, and the cost can be effectively reduced. The skin care gel has the advantages of simple preparation method steps and convenient operation, and the prepared skin care gel is crystal clear, has good stability, has good acne removing effect, and has the performance of safety and no stimulation to skin.
With the increasing number of patients diagnosed with colorectal cancer, the proportion of patients undergoing surgical resection with general anesthesia increased. However, the operation can lead tumor cells releasing into the blood or peritoneal implantation, and the impaired immune response can make patients susceptible to the development of tumor metastasis and recurrence which is the the main reason of death. It is well known that B lymphocytes and T lymphocytes are the main immune cells, and B lymphocytes by secreting antibodies are related to humoral immunity and T lymphocytes which play the most important role in antitumor are related to cell-mediated immunity. Surgery stress leads to metabolic and neuroendocrine changes causing significant depression of immunity. Although general anesthesia could reduce surgical stress, studies indicated general anesthetics including intravenous and inhalational agents both have variable effects on tumor cells growth by immuno-modulation and some cytokines. A number of studies have demonstrated deleterious effects on the function of lymphocytes associated with the administration of volatile inhalational anesthetic agents. It was suggested that the use of volatile inhalational agent may augment tumor cells growth by inhibiting the activity of lymphocytes, NK cells and dendritic cells which are important for recognizing, capturing and killing tumor cells, however, the alternative propofol has a converse (beneficial) effect by decreasing the plasma level of cytokines secreted by activated lymphocytes, macrophages and NK cells. The detailed mechanism of how volatile anesthetics affect the activity of antitumor cells remains unknown. Thus the investigators will conduct the clinical investigation to study the effect of volatile anesthetics on the immune response and metastasis in patients undergoing colorectal cancer resection, exploring molecular mechanism involved if inhalational anesthetics show an effect. The findings of this study would be valuable for anesthetic regimen guidance of colorectal cancer patients undergoing surgical resection in terms of long-term survival.
In this prospective randomized study, pediatric patients between 1- 10 years old who were scheduled to bilateral inguinal hernia surgery wil be enrolled the study. The patients wil randomly assign to receive an ultrasound-guided Ilioinguinal/iliohypogastric block group or caudal block group Ilioinguinal/iliohypogastric block was performed with 2 mg/kg bupivacaine as 0.25 % and total volum wil be divided equally for each side, Caudal block wil performe with bupivacaine 2 mg/kg as 0.2%. Supplemental analgesia will consist of as requred intraoperative remifentanyl, for recovery unit rescue tramadol, as requred at home ibuprofen. Patients wil be evaluated in the recovery unit for analgesia with FLACC pain scale, analgesic requirement, complications and parental satisfaction. Parents will be also called for analgesia and satisfaction after discharge of the patients in first 24 hours. The evaluation will be performed by a researcher whom does not know which participants belong to the caudal or ilioinguinal/iliohypogastric nerve block group